Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in ...
Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses [2] SINGAPORE, June 27, 2023 /PRNewswire/ -- Independent ...
The CAR T-cell therapy is intended to treat relapsed or refractory diffuse large B-cell lymphoma. Credit: Chinnapong / Shutterstock. · Clinical Trials Arena · Chinnapong / Shutterstock. Australian ...
A phase 2 clinical trial has delivered some of the most striking results yet reported in early-stage classical Hodgkin ...
Australian researchers have used an innovative genome-wide screening approach to identify genes, and their encoded proteins, that play critical roles in the prevention of lymphoma development, ...
It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
SINGAPORE, April 23, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that Minjuvi® (tafasitamab), in combination with rituximab and ...
The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients. 2 ...
Australia's Therapeutic Goods Administration has registered MINJUVI (tafasitamab) in combination with rituximab and lenalidomide for treating adults with relapsed or refractory follicular lymphoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results